Citadel Advisors’s Bioventus BVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$251K Buy
+26,600
New +$254K ﹤0.01% 11533
2025
Q2
Sell
-5,700
Closed -$52.2K 12675
2025
Q1
$52.2K Sell
5,700
-15,300
-73% -$153K ﹤0.01% 12272
2024
Q4
$221K Sell
21,000
-20,400
-49% -$241K ﹤0.01% 10273
2024
Q3
$495K Buy
41,400
+4,200
+11% +$36.3K ﹤0.01% 8277
2024
Q2
$214K Buy
37,200
+9,900
+36% +$54.3K ﹤0.01% 9784
2024
Q1
$142K Buy
27,300
+23,300
+583% +$114K ﹤0.01% 10845
2023
Q4
$21.1K Sell
4,000
-2,100
-34% -$8.31K ﹤0.01% 12579
2023
Q3
$20.1K Sell
6,100
-100
-2% -$351 ﹤0.01% 12624
2023
Q2
$17.9K Buy
+6,200
New +$11.9K ﹤0.01% 12832
2023
Q1
Sell
-4,500
Closed -$11.7K 14752
2022
Q4
$11.7K Buy
+4,500
New +$19.6K ﹤0.01% 13554

Other funds holding BVS

Citadel Advisors's BVS Position: Q2 2026 in Review

Citadel Advisors sold out of Bioventus (BVS) in Q2 2026, closing a stake of 17,085 shares — an estimated $163K sold.

Citadel Advisors first reported a position in BVS in Q2 2021 and held it in 18 quarters. The position peaked at $3.21M in Q3 2024. 156 funds tracked by Wall St. Rank hold BVS as of Q2 2026.

  • Citadel Advisors reported no remaining Bioventus position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 17,085 Bioventus shares in Q2 2026, an estimated $163K.
  • Citadel Advisors first reported a position in Bioventus in Q2 2021 and held it in 18 quarters.
  • Citadel Advisors's Bioventus position peaked at $3.21M in Q3 2024.
  • 156 funds tracked by Wall St. Rank held Bioventus as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.